Kasralainy School of medicine, Cairo, Egypt.
Department of Neurosurgery, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom.
World Neurosurg. 2023 Aug;176:e543-e547. doi: 10.1016/j.wneu.2023.05.097. Epub 2023 Jun 1.
Glioblastoma multiforme (GBM) is the predominant malignant brain tumor originating intracranially. The established first-line treatment postsurgery is concurrent chemoradiation as a definitive measure. However, recurrent GBM's pose a challenge for clinicians who rely on institutional experience to determine the most suitable course of action. Second-line chemotherapy may be administered with or without surgery depending on the institution's practice. This study aims to present our tertiary center institution's experience with recurrent GBM patients who underwent redo surgery.
In this retrospective study we analyzed the surgical and oncological data of patients with recurrent GBM who underwent redo surgery at the Royal Stoke University Hospitals between 2006 and 2015. The group 1 (G1) comprised the reviewed patients, while a control group (G2) was randomly selected, matching the reviewed group by age, primary treatment, and progression-free survival (PFS). The study collected data on various parameters, including overall survival, PFS, extent of surgical resection, and postoperative complications.
This retrospective study included 30 patients in G1 and 32 patients in G2, matched based on age, primary treatment, and PFS. The study found that the overall survival for the G1 group from the time of first diagnosis was 109 weeks (45-180) compared to 57 weeks (28-127) in the G2 group. The incidence of postoperative complications after the second surgery was 57%, which included hemorrhage, infarction, worsening neurology due to edema, cerebrospinal fluid leak, and wound infection. Furthermore, 50% of the patients in the G1 group who underwent redo surgery received second-line chemotherapy.
Our study found that redo surgery for recurrent GBM is a viable treatment option for a select group of patients with good performance status, longer PFS from primary treatment, and compressive symptoms. However, the use of redo surgery varies depending on the institution. A well-designed randomized controlled trial in this population would help establish the standard of surgical care.
多形性胶质母细胞瘤(GBM)是源自颅内的主要恶性脑肿瘤。术后的标准一线治疗是同步放化疗作为确定性治疗措施。然而,复发性 GBM 给临床医生带来了挑战,他们依赖机构经验来确定最合适的治疗方案。二线化疗可以根据机构的实践情况选择手术或不手术。本研究旨在介绍我们的三级中心机构对接受再手术的复发性 GBM 患者的经验。
在这项回顾性研究中,我们分析了 2006 年至 2015 年在皇家斯托克大学医院接受再手术的复发性 GBM 患者的手术和肿瘤学数据。第 1 组(G1)包括接受复查的患者,而对照组(G2)则是随机选择的,与复查组按年龄、初始治疗和无进展生存期(PFS)相匹配。研究收集了各种参数的数据,包括总生存期、PFS、手术切除范围和术后并发症。
这项回顾性研究包括 G1 组的 30 例患者和 G2 组的 32 例患者,按年龄、初始治疗和 PFS 相匹配。研究发现,G1 组从首次诊断开始的总生存期为 109 周(45-180),而 G2 组为 57 周(28-127)。第二次手术后的并发症发生率为 57%,包括出血、梗塞、水肿引起的神经恶化、脑脊液漏和伤口感染。此外,G1 组中有 50%接受再手术的患者接受了二线化疗。
我们的研究发现,对于表现状态良好、初始治疗后 PFS 较长且有压迫症状的复发性 GBM 患者,再手术是一种可行的治疗选择。然而,再手术的使用因机构而异。在该人群中进行精心设计的随机对照试验将有助于建立手术护理的标准。